Answers are grounded in this paper and cite their sources.
Among patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Lähteenvuo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: